Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension

Critical Reviews in Clinical Laboratory Sciences

Volumn 44, Issue 1, 2007, Pages 1-85

  Rossi, Gian Paolo ^a,c   Seccia, Teresa M ^b   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Aldosterone; Angiotensin; Cushing's syndrome; Hypertension; Renin; Renovascular

Indexed keywords

AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOXAZOSIN; FLUDROCORTISONE; GROWTH HORMONE; HALOPERIDOL; HYDRALAZINE; LABETALOL; METHYLDOPA; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; POTASSIUM; PRAZOSIN; SPIRONOLACTONE; TACROLIMUS; UNINDEXED DRUG;

ACROMEGALY; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ALDOSTERONE RELEASE; APPARENT MINERALOCORTICOID EXCESS SYNDROME; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CHEMOLUMINESCENCE; CIRCADIAN RHYTHM; CUSHING SYNDROME; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ELECTROLYTE BLOOD LEVEL; FLUOROMETRY; GENETIC ANALYSIS; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; HYPERTHYROIDISM; HYPOKALEMIA; HYPOTHYROIDISM; IMMUNORADIOMETRIC ASSAY; KIDNEY BIOPSY; KIDNEY DISEASE; LABORATORY TEST; LIDDLE SYNDROME; LOW DRUG DOSE; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; PREGNANCY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEINURIA; PSEUDOHYPOALDOSTERONISM; RENOPARENCHYMAL HYPERTENSION; RENOVASCULAR HYPERTENSION; REVASCULARIZATION; REVIEW; SIDE EFFECT; SODIUM LOAD; SODIUM RETENTION; STATISTICAL ANALYSIS; SYNCOPE; UREMIA; URINE SEDIMENT;

CLINICAL LABORATORY TECHNIQUES; CUSHING SYNDROME; ENDOCRINE SYSTEM DISEASES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTENSION, RENOVASCULAR; KIDNEY DISEASES; PARAGANGLIOMA;

EID: 33845798419     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360600931831     Document Type: Review

References (418)

1. Bech K, Hilden T. The frequency of secondary hypertension. Acta Med Scand 1975; 197: 65-69.
2. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976; 2: 554-556.
3. Laugesen LP, Hansen AG, Jensen H, Petersen A, Tonnesen KH. The prevalence of secondary hypertension in elderly hypertensive patients. Acta Med Scand Suppl 1983; 676: 161-177.
4. Dluhy RG. Uncommon forms of secondary hypertension in older patients. Am J Hypertens 1998; 11: 52S-56S.
5. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202.
6. Davidson RA, Barri YM, Wilcox CS. The simplified captopril test: an effective tool to diagnose renovascular hypertension. Am J Kidney Dis 1994; 24: 660-664.
7. Dal Palu C, Pessina AC, Rossi GP. The diagnostic approach to the hypertensive patient. Contrib Nephrol 1987; 54: 32-37.
8. Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures. principles and applications. Ann Intern Med 1981; 94: 557-592.
9. Seccia TM, Rossi GP. Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. Crit Rev Clin Lab Sci 2005; 42: 393-452.
10. Conn JW. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954. J Lab Clin Med 1990; 116: 253-267.
11. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 2002; 34: 1577-1584.
12. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002; 970: 89-100.
13. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16: 80-86.
14. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.
15. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF, Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050.
16. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16: 104-107.
17. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172.
18. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. a detectable cause of curable "essential" hypertension. JAMA 1965; 193: 200-206.
19. Conn JW. The evolution of primary aldosteronism: 1954-1967. Harvey Lect 1966; 62: 257-291.
20. Conn JW, Cohen EL, Rovner DR. Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. JAMA 1985; 253: 558-566.
21. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-298.
22. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318.
23. Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828-1834.
24. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF, Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
25. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
26. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep 2004; 6: 1-4.
27. Rossi G, Bernini G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Mantero F. Prevalence of primary aldosteronism (PA) in newly diagnosed hypertensive patients: Results of a nationwide survey in Italy. J Hypertens 2004; 22: S148 (abst.).
28. Rousseau G, Baxter JD, Funder JW, Edelman IS, Tomkins GM. Glucocorticoid and mineralocorticoid receptors for aldosterone. J Steroid Biochem 1972; 3: 219-227.
29. Funder JW, Feldman D, Edelman IS. The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 1973; 92: 994-1004.
30. Pessina AC, Corgnati A, Dal Palu C. Sodium-potassium ratio and electrical potential of colon in the screening of hyperaldosteronism. G Ital Cardiol 1974; 4: 167-172.
31. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
32. Pagano P. NAD(P)H oxidase: marker of the dedifferentiated neointimal smooth muscle cell? Arterioscler Thromb Vasc Biol 2001; 21: 175-177.
33. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999; 84: 4341-4344.
34. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 2005; 12: 149-159.
35. Haenel LC, Hermayer KL. A case of unilateral adrenal hyperplasia: the diagnostic dilemma of hyperaldosteronism. Endocr Pract 2000; 6: 153-158.
36. Morioka M, Kobayashi T, Sone A, Furukawa Y, Tanaka H. Primary aldosteronism due to unilateral adrenal hyperplasia: report of two cases and review of the literature. Endocr J 2000; 47: 443-449.
37. Katayama Y, Takata N, Tamura T, Yamamoto A, Hirata F, Yasuda H, Matsukuma S, Daido Y, Sasano H. A case of primary aldosteronism due to unilateral adrenal hyperplasia. Hypertens Res 2005; 28: 379-384.
38. Hirono Y, Doi M, Yoshimoto T, Kanno K, Himeno Y, Taki K, Sasano H, Hirata Y. A case with primary aldosteronism due to unilateral multiple adrenocortical micronodules. Endocr J 2005; 52: 435-439.
39. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005; 16: 114-119.
40. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001; 2: 156-169.
41. Rossi GP, Ganzaroli C, Miotto D, De Toni R, Palumbo G, Feltrin GP, Mantero F, Pessina AC. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens 2006; 24: 371-379.
42. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460-484.
43. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273-285.
44. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22: 863-869.
45. Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11: 894-896.
46. Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004; 150: 329-337.
47. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16: 86-91.
48. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88: 2489-94.
49. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004; 22: 377-381.
50. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89: 4221-4226.
51. Hartman D, Sagnella GA, Chesters CA, Macgregor GA. Direct renin assay and plasma renin activity assay compared. Clin Chem 2004; 50: 2159-2161.
52. Bizollon CA, Riviere JF, Franchimont P, Faure A, Claustrat B. Solid phase radioimmunoassay of plasma aldosterone. Steroids 1974; 23: 809-821.
53. Lijnen P, Amery A, Fagard R, Corvol P. Direct radioimmunoassay of plasma aldosterone in normal subjects. Clin Chim Acta 1978; 84: 305-314.
54. Katz FH, Romfh P, Smith JA. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab 1975; 40: 125-134.
55. Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, Mechelhoff D, Tauber R, Diederich S. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50: 1650-1655.
56. Stabler TV, Siegel AL. Chemiluminescence immunoassay of aldosterone in serum. Clin Chem 1991; 37: 1987-1989.
57. Atherden SM, Corrie JE, Jones DB, Al Dujaili EA, Edwards CR. Development and application of a direct radioimmunoassay for aldosterone in saliva. Steroids 1985; 46: 845-55.
58. Few JD, Unwin RJ, Carmichael DJ, James VH. Diurnal fluctuation in saliva aldosterone concentration. J Steroid Biochem 1987; 26: 265-271.
59. Vecsei P, Penke B, Joumaah A. Radioimmunoassay of free aldosterone and of its 18-oxoglucuronide in human urine. Experientia 1972; 28: 622-624.
60. Gomez-Sanchez CE, Holland OB. Urinary tetrahydroaldosterone and aldosterone-18-glucuronide excretion in white and black normal subjects and hypertensive patients. J Clin Endocrinol Metab 1981; 52: 214-219.
61. Ishida J, Sonezaki S, Yamaguchi M, Yoshitake T. High-performance liquid chromatographic determination of 3 alpha, 5 beta-tetrahydroaldosterone in human urine with chemiluminescence detection. Analyst 1992; 117: 1719-1724.
62. Mattingly D, Martin H, Tyler CM. Estimation of urinary aldosterone using thin-layer chromatography and fluorimetry. J Clin Pathol 1993; 46: 1109-1112.
63. Cunningham SK, Sequeira SJ, Chambers J, Heffernan A, McKenna TJ. Optimisation of total urinary aldosterone estimation: comparison with other laboratory methods for assessment of mineralocorticoid status. J Steroid Biochem 1988; 31: 125-130.
64. Few JD, Wallis PJ, James VH. The relationship between salivary aldosterone and plasma free aldosterone concentrations. Clin Endocrinol (Oxf) 1986; 24: 119-126.
65. Stowasser M, Gordon RD. The aldosterone-renin ratio and primary aldosteronism. Mayo Clin Proc 2002; 77: 202-203.
66. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
67. Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495-511.
68. Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the reninangiotensin-aldosterone axis. J Clin Endocrinol Metab 1997; 82: 457-460.
69. Lyons DF, Kem DC, Brown RD, Hanson CS, Carollo ML. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 1983; 57: 892-896.
70. Racine MC, Douville P, Lebel M. Functional tests for primary aldosteronism: value of captopril suppression. Curr Hypertens Rep 2002; 4: 245-249.
71. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.
72. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24: 737-745.
73. Iwaoka T, Umeda T, Naomi S, Inoue J, Sasaki M, Yamauchi J, Sato T. The usefulness of the captopril test as a simultaneous screening for primary aldosteronism and renovascular hypertension. Am J Hypertens 1993; 6: 899-906.
74. Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 1992; 36: 499-503.
75. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37: 1440-1443.
76. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, Perazzoli F, Pessina AC. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49: 713-723.
77. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-315.
78. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6: 717-23.
79. Young WF, Jr. Primary aldosteronism: management issues. Ann NY Acad Sci 2002; 970: 61-76.
80. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21: 995-1012.
81. Lockhart ME, Smith JK, Kenney PJ. Imaging of adrenal masses. Eur J Radiol 2002; 41: 95-112.
82. Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, Hahn PF, Boland GW. Pheochromocytoma: an imaging chameleon. Radiographics 2004; 24 Suppl 1: S87-S99.
83. Sahdev A, Reznek RH. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol Metab 2004; 15: 271-276.
84. Renken NS, Krestin GP. Magnetic resonance imaging of the adrenal glands. Semin Ultrasound CT MR 2005; 26: 162-171.
85. Rossi GP, Chiesura-Corona M, Tregnaghi A, Zanin L, Perale R, Soattin S, Pelizzo MR, Feltrin GP, Pessina AC. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens 1993; 7: 357-363.
86. Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, Findling JW. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001; 86: 1066-1071.
87. Gross MD, Shapiro B, Freitas JE. Limited significance of asymmetric adrenal visualization on dexamethasone-suppression scintigraphy. J Nucl Med 1985; 26: 43-48.
88. Vetter H, Fischer M, Galanski M, Stieber U, Tenschert W, Baumgart P, Winterberg B, Vetter W. Primary aldosteronism: diagnosis and noninvasive lateralization procedures. Cardiology 1985; 72 Suppl 1: 57-63.
89. Mansoor GA, Malchoff CD, Arici MH, Karimeddini MK, Whalen GF. Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 2002; 15: 459-464.
90. Lumachi F, Marzola MC, Zucchetta P, Tregnaghi A, Cecchin D, Favia G, Bui F. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI. Nucl Med Commun 2003; 24: 683-688.
91. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86: 1083-1090.
92. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005; 25 Suppl 1: S143-S158.
93. Young WF, Jr., Stanson AW, Grant CS, Thompson GB, Van Heerden JA. Primary aldosteronism: adrenal venous sampling. Surgery 1996; 120: 913-919.
94. Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, Linehan WM, Doppman JL, Gill JJ, Jr. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85: 4526-33.
95. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after "nonselective" screening of hypertensive patients. J Hypertens 2003; 21: 2149-57.
96. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003; 24: 539-553.
97. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983; 58: 802-804.
98. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 1986; 220: 225-232.
99. Smythe GA, Edwards G, Graham P, Lazarus L. Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine. Clin Chem 1992; 38: 486-492.
100. Kudva YC, Sawka AM, Young WF, Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88: 4533-4539.
101. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644.
102. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med 2000; 30: 648-652.
103. Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6: 477-484.
104. Bravo EL. Pheochromocytoma: an approach to antihypertensive management. Ann NY Acad Sci 2002; 970: 1-10.
105. Dluhy RG, Lawrence JE, Williams GH. Endocrine hypertension. In Larsen PR, Kronenberg HM, Melmed S, Polonski KS, Eds. Williams Textbook of Endocrinology, 10th Ed., Pp 552-586. Philadelphia: Saunders, 2003.
106. Crout JR, Sjoerdsma A. Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 1964; 43: 94-102.
107. Bravo EL, Tarazi RC, Gifford RW, Stewart BH. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 1979; 301: 682-686.
108. Page LB, Raker JW, Berberich FR. Pheochromocytoma with predominant epinephrine secretion. Am J Med 1969; 47: 648-652.
109. Zanin L, Rossi G, Poletti A, Piotto A, Chiesura-Corona M, Pessina AC. Necrosis of a phaeochromocytoma associated with spontaneous remission of diabetes and hypertension. Clin Endocrinol (Oxf) 1993; 39: 613-617.
110. Bravo EL, Tarazi RC, Fouad FM, Textor SC, Gifford RW, Jr., Vidt DG. Blood pressure regulation in pheochromocytoma. Hypertension 1982; 4: 193-199.
111. Johnson MD, Smith PG, Mills E, Schanberg SM. Paradoxical elevation of sympathetic activity during catecholamine infusion in rats. J Pharmacol Exp Ther 1983; 227: 254-259.
112. Prokocimer PG, Maze M, Hoffman BB. Role of the sympathetic nervous system in the maintenance of hypertension in rats harboring pheochromocytoma. J Pharmacol Exp Ther 1987; 241: 870-874.
113. Tsujimoto G, Honda K, Hoffman BB, Hashimoto K. Desensitization of postjunctional alpha 1-and alpha 2-adrenergic receptor-mediated vasopressor responses in rat harboring pheochromocytoma. Circ Res 1987; 61: 86-98.
114. Langer SZ, Cavero I, Massingham R. Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 1980; 2: 372-382.
115. Grassi G, Seravalle G, Turri C, Mancia G. Sympathetic nerve traffic responses to surgical removal of pheochromocytoma. Hypertension 1999; 34: 461-465.
116. Massart PE, Hodeige D, Donckier J. Adrenomedullin: view on a novel vasodilatory peptide with natriuretic properties. Acta Cardiol 1996; 51: 259-269.
117. Khan AI, Kato J, Kitamura K, Kangawa K, Eto T. Hypotensive effect of chronically infused adrenomedullin in conscious Wistar-Kyoto and spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1997; 24: 139-142.
118. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991; 70: 33-45.
119. Bravo EL, Gifford RW, Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1298-303.
120. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329: 1531-1538.
121. Evans DB, Lee JE, Merrell RC, Hickey RC. Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management. Endocrinol Metab Clin North Am 1994; 23: 167-76.
122. Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. Annu Rev Physiol 2000; 62: 377-411.
123. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 162: 1582-1586.
124. Rossi G, Deppieri O, Pessina AC. Effect of haemolysis on high-performance liquid chromatography measurements of free plasma catecholamines. J Chromatogr 1986; 380: 117-121.
125. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-1434.
126. Gagel RF, Tashjian AH, Jr., Cummings T, Papathanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ, Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988; 318: 478-484.
127. Eisenhofer G, Walther M, Keiser HR, Lenders JW, Friberg P, Pacak K. Plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Braz J Med Biol Res 2000; 33: 1157-1169.
128. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665-675.
129. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, Eisenhofer G. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995; 123: 101-109.
130. Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhausl W, Roden M. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 2000; 160: 2957-2963.
131. Dal Palu C, Pessina AC, Semplicini A, Hlede M, Morandin F, Palatini P, Sperti G, Rossi GP. Intravenous labetalol in severe hypertension. Br J Clin Pharmacol 1982; 13: 97S-99S.
132. Feldman JM. Falsely elevated urinary excretion of catecholamines and metanephrines in patients receiving labetalol therapy. J Clin Pharmacol 1987; 27: 288-292.
133. Cook FJ, Chandler DW, Snyder DK. Effect of buspirone on urinary catecholamine assays. N Engl J Med 1995; 332: 401.
134. O'Connor DT, Frigon RP. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 1984; 259: 3237-3247.
135. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145-1151.
136. Parmer RJ, Xi XP, Wu HJ, Helman LJ, Petz LN. Secretory protein traffic. Chromogranin A contains a dominant targeting signal for the regulated pathway. J Clin Invest 1993; 92: 1042-1054.
137. Aardal S, Aardal NP, Larsen TH, Angeletti RH, Stridsberg M, Taupenot L, Aunis D, Helle KB. Human pheochromocytoma: different patterns of catecholamines and chromogranins in the intact tumour, urine and serum in clinically unsuspected cases. Scand J Clin Lab Invest 1996; 56: 511-523.
138. Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 2000; 36: 1045-1052.
139. Rao F, Keiser HR, O'Connor DT. Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. Ann NY Acad Sci 2002; 971:530-2.: 530-532.
140. Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994; 78: 1139-1144.
141. Nishikimi T, Kitamura K, Saito Y, Shimada K, Ishimitsu T, Takamiya M, Kangawa K, Matsuo H, Eto T, Omae T, Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. Hypertension 1994; 24: 600-604.
142. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94: 2158-2161.
143. Letizia C, De Toma G, Caliumi C, Cerci S, Massa R, Loria RD, Alo P, Marinoni EM, Diacinti D, D'Erasmo E. Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma. Horm Metab Res 2001; 33: 290-294.
144. Lawrence AM. Glucagon provocative test for pheochromocytoma. Ann Intern Med 1967; 66: 1091-1096.
145. Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford RW, Jr. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305: 623-626.
146. Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994; 23: 271-283.
147. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA, Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-856.
148. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-460.
149. Neumann HP, Eng C, Mulligan LM, Glavac D, Zauner I, Ponder BA, Crossey PA, Maher ER, Brauch H. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 1995; 274: 1149-1151.
150. Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996; 335: 943-951.
151. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der MA, Taschner PE, Rubinstein WS, Myers EN, Richard CW, III, Cornelisse CJ, Devilee P, Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851.
152. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F, Maher ER. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001; 357: 1181-1182.
153. Neumann HP, et al. for the Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-1466.
154. Schiavi F et al. for the European-American Paraganglioma Study Group. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005; 294: 2057-2063.
155. Lairmore TC, Ball DW, Baylin SB, Wells SA, Jr. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 1993; 217: 595-601.
156. Aprill BS, Drake AJ, III, Lasseter DH, Shakir KM. Silent adrenal nodules in von Hippel-Lindau disease suggest pheochromocytoma. Ann Intern Med 1994; 120: 485-487.
157. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996; 120: 1064-1070.
158. Arnaldi G, Masini AM, Giacchetti G, Taccaliti A, Faloia E, Mantero F. Adrenal incidentaloma. Braz J Med Biol Res 2000; 33: 1177-1189.
159. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147: 1-10.
160. Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int 1991; 40: 544-556.
161. Remine WH, Chong GC, Van Heerden JA, Sheps SG, Harrison EG, Jr. Current management of pheochromocytoma. Ann Surg 1974; 179: 740-748.
162. Nativ O, Grant CS, Sheps SG, O'Fallon JR, Farrow GM, Van Heerden JA, Lieber MM. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer 1992; 69: 2683-2687.
163. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 1989; 7: 1720-1725.
164. Salmenkivi K, Arola J, Voutilainen R, Ilvesmaki V, Haglund C, Kahri AI, Heikkila P, Liu J. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 2001; 86: 2231-2235.
165. deS SP, Denker J, Bravo EL, Graham RM. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 1995; 96: 2503-2509.
166. Alcazar JM, Rodicio JL. How to handle renovascular hypertension. J Hypertens 2001; 19: 2109-2111.
167. Pickering TG. The role of laboratory testing in the diagnosis of renovascular hypertension. Clin Chem 1991; 37: 1831-1837.
168. Carmichael P, Carmichael AR. Atherosclerotic renal artery stenosis: from diagnosis to treatment. Postgrad Med J 1999; 75: 527-536.
169. Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet 1994; 344: 237-239.
170. Helin KH, Tikkanen I, von Knorring JE, Lepantalo MJ, Liewendahl BK, Laasonen LS, Fyhrquist FY, Tikkanen T. Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998; 16: 1523-1529.
171. Eardley KS, Lipkin GW. Atherosclerotic renal artery stenosis: is it worth diagnosing? J Hum Hypertens 1999; 13: 217-220.
172. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001; 135: 401-411.
173. Rossi GP, Pavan E, Chiesura-Corona M, Bader M, Paganini G, Cesari M, De Toni R, Feltrin GP, Ganten D, Pessina AC. Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. Clin Sci (Lond) 1997; 93: 435-443.
174. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in 't Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998; 129: 705-711.
175. Textor SC. Epidemiology and clinical presentation. Semin Nephrol 2000; 20: 426-431.
176. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344: 431-442.
177. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365-1377.
178. Chiesura-Corona M, Feltrin GP, Savastano S, Miotto D, Torraco A, Castellan L, Rossi GP. Excess prevalence of supraaortic artery lesions in renovascular hypertension: an arteriographic study. Cardiovasc Intervent Radiol 1994; 17: 264-270.
179. Rossi GP, Rossi A, Zanin L, Calabro A, Feltrin GP, Pessina AC, Crepaldi G, Dal Palu C. Excess prevalence of extracranial carotid artery lesions in renovascular hypertension. Am J Hypertens 1992; 5: 8-15.
180. Harding MB, Smith LR, Himmelstein SI, Harrison K, Phillips HR, Schwab SJ, Hermiller JB, Davidson CJ, Bashore TM. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992; 2: 1608-1616.
181. Choudhri AH, Cleland JG, Rowlands PC, Tran TL, McCarty M, al Kutoubi MA. Unsuspected renal artery stenosis in peripheral vascular disease. BMJ 1990; 301: 1197-1198.
182. Zierler RE, Bergelin RO, Isaacson JA, Strandness DE, Jr. Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. J Vasc Surg 1994; 19: 250-257.
183. Caps MT, Zierler RE, Polissar NL, Bergelin RO, Beach KW, Cantwell-Gab K, Casadei A, Davidson RC, Strandness DE, Jr. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int 1998; 53: 735-742.
184. Olin JW, Melia M, Young JR, Graor RA, Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990; 88: 46N-51N.
185. Aurell M. Screening for secondary hypertension. Curr Hypertens Rep 1999; 1: 461.
186. Maxwell MH, Bleifer KH, Franklin SS, Varady PD. Cooperative study of renovascular hypertension. Demographic analysis of the study. JAMA 1972; 220: 1195-1204.
187. Svetkey LP, Helms MJ, Dunnick NR, Klotman PE. Clinical characteristics useful in screening for renovascular disease. South Med J 1990; 83: 743-747.
188. Textor SC. Pathophysiology of renal failure in renovascular disease. Am J Kidney Dis 1994; 24: 642-651.
189. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair D, Cole P. Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association. Circulation 2002; 106: 1572-1585.
190. de Leeuw PW. On the significance of renal vein renins in renovascular hypertension. J Hypertens 2002; 20: 843-845.
191. Vaughan ED, Jr., Buhler FR, Laragh JH, Sealey JE, Baer L, Bard RH. Renovascular hypertension: renin measurements to indicate hypersecretion and contralateral suppression, estimate renal plasma flow, and score for surgical curability. Am J Med 1973; 55: 402-414.
192. Vaughan ED, Jr., Carey RM, Ayers CR, Peach MJ, Tegtmeyer CJ, Wellons HA, Jr. Physiologic definition of blood pressure response to renal revascularization in patients with renovascular hypertension. Kidney Int Suppl 1979; S83-S92.
193. Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS, Preibisz JJ, Laragh JH. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80: 633-644.
194. Postma CT, van der Steen PH, Hoefnagels WH, de Boo T, Thien T. The captopril test in the detection of renovascular disease in hypertensive patients. Arch Intern Med 1990; 150: 625-628.
195. Svetkey LP, Wilkinson R, Jr., Dunnick NR, Smith SR, Dunham CB, Lambert M, Klotman PE. Captopril renography in the diagnosis of renovascular disease. Am J Hypertens 1991; 4: 711S-715S.
196. Stephan D, Welsch M, Decker N, Brule JM, Jahn C, Grima M, Imbs JL. Captopril test for detecting renal artery stenosis: changes in plasma renin concentration. Arch Mal Coeur Vaiss 1993; 86: 1249-1252.
197. Schreij G, van Es PN, Schiffers PM, Lavrijssen AT, de Leeuw PW. 'Captopril test', with blood pressure and peripheral renin as response variables in hypertensive patients with suspected renal artery stenosis. J Hum Hypertens 1995; 9: 741-746.
198. Dondi M, Levorato M, Corbelli C, Zagni P, Zuccala A, Gaggi R, Marchetta F, Losinno F, Stella A, Mirelli M. Detection of renal artery stenosis by means of captopril renography with 99mTc-DTPA. Contrib Nephrol 1990; 79: 181-185.
199. Mann SJ, Pickering TG, Sos TA, Uzzo RG, Sarkar S, Friend K, Rackson ME, Laragh JH. Captopril renography in the diagnosis of renal artery stenosis: accuracy and limitations. Am J Med 1991; 90: 30-40.
200. Nitzsche E, Grosser G, Rump C, Strauss E, Meyer E, Keller E, Moser E. Captopril-renal function scintigraphy in the clarification of arterial hypertension. Radiologe 1991; 31: 141-146.
201. Setaro JF, Chen CC, Hoffer PB, Black HR. Captopril renography in the diagnosis of renal artery stenosis and the prediction of improvement with revascularization. The Yale Vascular Center experience. Am J Hypertens 1991; 4: 698S-705S.
202. Dondi M, Fanti S, Barozzi L, De Fabritiis A, Losinno F, Pavlica P, Monetti N, Zuccala A. Evaluation by captopril renal scintigraphy and echo-Doppler flowmetry of hypertensive patients at high risk for renal artery stenosis. J Nucl Biol Med 1992; 36: 309-314.
203. Fommei E, Ghione S, Hilson AJ, Mezzasalma L, Oei HY, Piepsz A, Volterrani D. Captopril radionuclide test in renovascular hypertension: a European multicentre study. European Multicentre Study Group. Eur J Nucl Med 1993; 20: 617-623.
204. Kahn D, Ben Haim S, Bushnell DL, Madsen MT, Kirchner PT. Captopril-enhanced 99Tcm-MAG3 renal scintigraphy in subjects with suspected renovascular hypertension. Nucl Med Commun 1994; 15: 515-528.
205. Mittal BR, Kumar P, Arora P, Kher V, Singhal MK, Maini A, Das BK. Role of captopril renography in the diagnosis of renovascular hypertension. Am J Kidney Dis 1996; 28: 209-213.
206. Pedersen EB, Egeblad M, Jorgensen J, Nielsen SS, Spencer ES, Rehling M. Diagnosing renal artery stenosis: a comparison between conventional renography, captopril renography and ultrasound Doppler in a large consecutive series of patients with arterial hypertension. Blood Press 1996; 5: 342-348.
207. Tremel F, Caravel JP, Siche JP, Chevallier M, Mallion JM. Diagnostic value of renal scintigraphy with MAG 3 and DTPA in the diagnosis of renal artery stenosis. Arch Mal Coeur Vaiss 1996; 89: 1035-1039.
208. Kaplan-Pavlovcic S, Nadja C. Captopril renography and duplex Doppler sonography in the diagnosis of renovascular hypertension. Nephrol Dial Transplant 1998; 13: 313-317.
209. Gezici A, Ersay A, Antevska E, Heidental GK, Schreij G, Demirtas OC. Quantitative residual cortical activity measurement: appropriate test for diagnosis of renal artery stenosis? Urol Int 1999; 62: 1-7.
210. Bongers V, Bakker J, Beutler JJ, Beek FJ, De Klerk JM. Assessment of renal artery stenosis: comparison of captopril renography and gadolinium-enhanced breath-hold MR angiography. Clin Radiol 2000; 55: 346-353.
211. Postma CT, van Aalen J, de Boo T, Rosenbusch G, Thien T. Doppler ultrasound scanning in the detection of renal artery stenosis in hypertensive patients. Br J Radiol 1992; 65: 857-860.
212. Miralles M, Santiso A, Gimenez A, Riambau V, Saez A, Daumal J, Cairols MA. Renal duplex scanning: correlation with angiography and isotopic renography. Eur J Vasc Surg 1993; 7: 188-194.
213. Kliewer MA, Tupler RH, Carroll BA, Paine SS, Kriegshauser JS, Hertzberg BS, Svetkey LP. Renal artery stenosis: analysis of Doppler waveform parameters and tardus-parvus pattern. Radiology 1993; 189: 779-787.
214. Olin JW, Piedmonte MR, Young JR, DeAnna S, Grubb M, Childs MB. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 1995; 122: 833-838.
215. Spies KP, Fobbe F, El Bedewi M, Wolf KJ, Distler A, Schulte KL. Color-coded duplex sonography for noninvasive diagnosis and grading of renal artery stenosis. Am J Hypertens 1995; 8: 1222-1231.
216. Strotzer M, Fellner CM, Geissler A, Gmeinwieser J, Kohler SM, Kramer BK, Kromer EP. Noninvasive assessment of renal artery stenosis. A comparison of MR angiography, color Doppler sonography, and intraarterial angiography. Acta Radiol 1995; 36: 243-247.
217. Strunk H, Jaeger U. Duplex ultrasonographic diagnosis of renal artery stenosis by intrarenal acceleration determination and recognition of the tardus-parvus phenomenon with special regard to multiple renal arteries. Rofo 1995; 162: 420-428.
218. Lucas P, Blome S, Roche J. Intra-renal Doppler wave-form analysis as a screening test for renal artery stenosis. Australas Radiol 1996; 40: 276-282.
219. Postma CT, Bijlstra PJ, Rosenbusch G, Thien T. Pattern recognition of loss of early systolic peak by Doppler ultrasound has a low sensitivity for the detection of renal artery stenosis. J Hum Hypertens 1996; 10: 181-184.
220. Miralles M, Cairols M, Cotillas J, Gimenez A, Santiso A. Value of Doppler parameters in the diagnosis of renal artery stenosis. J Vasc Surg 1996; 23: 428-435.
221. Vigna C, Pacilli MA, Testa M, Langialonga T, Salvatori MP, Lanna P, Russo A, Perna GP, Fanelli R, Loperfido F. Comparison of steerable continuous-wave versus pulsed-wave Doppler ultrasonography to renal artery angiography in diagnosing renal artery stenosis. Am J Cardiol 1998; 81: 365-367.
222. Oliva VL, Soulez G, Lesage D, Nicolet V, Roy MC, Courteau M, Froment D, Rene PC, Therasse E, Carignan L. Detection of renal artery stenosis with Doppler sonography before and after administration of captopril: value of early systolic rise. AJR Am J Roentgenol 1998; 170: 169-175.
223. Galanski M, Prokop M, Chavan A, Schaefer C, Jandeleit K, Olbricht C. Accuracy of CT angiography in the diagnosis of renal artery stenosis. Rofo 1994; 161: 519-25.
224. Olbricht CJ, Paul K, Prokop M, Chavan A, Schaefer-Prokop CM, Jandeleit K, Koch KM, Galanski M. Minimally invasive diagnosis of renal artery stenosis by spiral computed tomography angiography. Kidney Int 1995; 48: 1332-1337.
225. Kaatee R, Beek FJ, de Lange EE, van Leeuwen MS, Smits HF, van der Ven PJ, Beutler JJ, Mali WP. Renal artery stenosis: detection and quantification with spiral CT angiography versus optimized digital subtraction angiography. Radiology 1997; 205: 121-127.
226. Equine O, Beregi JP, Mounier-Vehier C, Gautier C, Desmoucelles F, Carre A. Importance of the echo-doppler and helical angioscanner of the renal arteries in the management of renovascular diseases. Results of a retrospective study in 113 patients. Arch Mal Coeur Vaiss 1999; 92: 1043-1045.
227. Postma CT, Joosten FB, Rosenbusch G, Thien T. Magnetic resonance angiography has a high reliability in the detection of renal artery stenosis. Am J Hypertens 1997; 10: 957-963.
228. Leung DA, Pelkonen P, Hany TF, Zimmermann G, Pfammatter T, Debatin JF. Value of image subtraction in 3D gadolinium-enhanced MR angiography of the renal arteries. J Magn Reson Imaging 1998; 8: 598-602.
229. Thornton J, O'Callaghan J, Walshe J, O'Brien E, Varghese JC, Lee MJ. Comparison of digital subtraction angiography with gadolinium-enhanced magnetic resonance angiography in the diagnosis of renal artery stenosis. Eur Radiol 1999; 9: 930-934.
230. De Cobelli F, Venturini M, Vanzulli A, Sironi S, Salvioni M, Angeli E, Scifo P, Garancini MP, Quartagno R, Bianchi G, Del Maschio A. Renal arterial stenosis: prospective comparison of color Doppler US and breath-hold, three-dimensional, dynamic, gadolinium-enhanced MR angiography. Radiology 2000; 214: 373-380.
231. Korst MB, Joosten FB, Postma CT, Jager GJ, Krabbe JK, Barentsz JO. Accuracy of normal-dose contrast-enhanced MR angiography in assessing renal artery stenosis and accessory renal arteries. AJR Am J Roentgenol 2000; 174: 629-634.
232. Goldblatt H. Hypertension of renal origin. Historical and experimental background. Am J Surg 1964; 107: 21-25.
233. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 1991; 17: 707-719.
234. Doyle AE, Duffy SG. Sodium balance and plasma renin activity during the development of twokidney Goldblatt hypertension in rats. Clin Exp Pharmacol Physiol 1980; 7: 293-304.
235. Pessina AC, Rossi GP. Real vein renin. In Martini L, Ed. Encyclopedia of Endocrine Diseases. Pp 198-203. Oxford: Academic Press, Elsevier Inc., 2004.
236. Welch WJ. The pathophysiology of renin release in renovascular hypertension. Semin Nephrol 2000; 20: 394-401.
237. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED, Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-652.
238. Case DB, Laragh JH. Reactive hyperreninemia in renovascular hypertension after angiotensin blockage with saralasin or converting enzyme inhibitor. Ann Intern Med 1979; 91: 153-160.
239. Rossi G, Semplicini A, Pessina AC, Perissinotto F, De Toni R, Feltrin G, Mozzato MG, Dal Palu C. Dynamic evaluation of the renin-angiotensin system with captopril in screening for renovascular hypertension. G Ital Cardiol 1985; 15: 472-477.
240. Radermacher J, Haller H. The right diagnostic work-up: investigating renal and renovascular disorders. J Hypertens Suppl 2003; 21: S19-S24.
241. Rossi GP, Bernini G, Caliumi C, Desideri GB, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, for the PAPY Study Investigators. A Prospective Study of The Prevalence of Primary Aldosteronism in 1125 Hypertensive Patients. J Am Coll Cardiol 2006; in press.
242. Davidson RA, Wilcox CS. Newer tests for the diagnosis of renovascular disease. JAMA 1992; 268: 3353-3358.
243. Elliott WJ, Martin WB, Murphy MB. Comparison of two noninvasive screening tests for renovascular hypertension. Arch Intern Med 1993; 153: 755-764.
244. Bijlstra PJ, Postma CT, de Boo T, Thien T. Clinical and biochemical criteria in the detection of renal artery stenosis. J Hypertens 1996; 14: 1033-1040.
245. Pickering TG, Sos TA, Vaughan ED, Jr., Case DB, Sealey JE, Harshfield GA, Laragh JH. Predictive value and changes of renin secretion in hypertensive patients with unilateral renovascular disease undergoing successful renal angioplasty. Am J Med 1984; 76: 398-404.
246. Wilcox CS. Functional testing: renin studies. Semin Nephrol 2000; 20: 432-436.
247. Rossi GP, Cesari M, Chiesura-Corona M, Miotto D, Semplicini A, Pessina AC. Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery. J Hypertens 2002; 20: 975-984.
248. Webb DJ, Cumming AM, Adams FC, Hodsman GP, Leckie BJ, Lever AF, Morton JJ, Murray GD, Robertson JI. Changes in active and inactive renin and in angiotensin II across the kidney in essential hypertension and renal artery stenosis. J Hypertens 1984; 2: 605-614.
249. Mann SJ, Pickering TG. Detection of renovascular hypertension. State of the art: 1992. Ann Intern Med 1992; 117: 845-853.
250. Semple PF, Dominiczak AF. Detection and treatment of renovascular disease: 40 years on. J Hypertens 1994; 12: 729-734.
251. Pickering TG, Sos TA, Vaughan ED, Jr., Laragh JH. Differing patterns of renal vein renin secretion in patients with renovascular hypertension, and their role in predicting the response to angioplasty. Nephron 1986; 44 Suppl 1: 8-11.
252. Hasbak P, Jensen LT, Ibsen H. Hypertension and renovascular disease: follow-up on 100 renal vein renin samplings. J Hum Hypertens 2002; 16: 275-280.
253. Rossi GP, Zanin L, Dessi-Fulgheri P, Savastano S, Cavazzana A, Prayer-Galetti T, Rappelli A, Pessina AC. A renin-secreting tumour with severe hypertension and cardiovascular disease: a diagnostic and therapeutic challenge. Clin Exp Hypertens 1993; 15: 325-338.
254. Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, Galanski M, Koch KM, Haller H. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344: 410-417.
255. Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause of renal failure? Annu Rev Med 2001; 52: 421-442.
256. Bardelli M, Jensen G, Volkmann R, Aurell M. Non-invasive ultrasound assessment of renal artery stenosis by means of the Gosling pulsatility index. J Hypertens 1992; 10: 985-989.
257. Eley JD, Kelly JH. Importance of incubation conditions in measuring renin activity. Clin Chem 1977; 23: 1944-1945.
258. Roding JH, Weterings T, van der HC. Plasma renin activity: temperature optimum at approximately 45 degrees C. Clin Chem 1997; 43: 1243-1244.
259. Emanuel RL, Williams GH. Should blood samples for assay of plasma renin activity be chilled? Clin Chem 1978; 24: 2042-2043.
260. Fyhrquist F, Puutula L. Effect of temperature on plasma renin samples. Clin Chem 1978; 24: 1202-1204.
261. Millar JA, Leckie BJ, Morton JJ, Jordan J, Tree M. A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta 1980; 101: 5-15.
262. Roulston JE, Sanger B, Wathen CG. The stability of angiotensin I formed at room temperature in the presence of ethylenediaminetetraacetate to subsequent incubation at 37 degrees C. J Clin Chem Clin Biochem 1983; 21: 703-707.
263. Stirati G, de Martino A, Mene P, Pierucci A, Simonetti BM, Feriozzi S, Manzi M, Cinotti GA. Plasma renin activity: effect of temperature during blood processing. J Clin Chem Clin Biochem 1983; 21: 529-531.
264. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci 1988; 42: 1683-1688.
265. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811-1819.
266. Bangham DR, Robertson I, Robertson JI, Robinson CJ, Tree M. An international collaborative study of renin assay: establishment of the international reference preparation of human renin. Clin Sci Mol Med Suppl 1975; 2: 135a-159s.
267. Menard J, Guyenne TT, Corvol P, Pau B, Simon D, Roncucci R. Direct immunometric assay of active renin in human plasma. J Hypertens Suppl 1985; 3: S275-S278.
268. Derkx FH, de Bruin RJ, van Gool JM, van den Hoek MJ, Beerendonk CC, Rosmalen F, Haima P, Schalekamp MA. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996; 42: 1051-1063.
269. Piffanelli A, Morganti A, Mantero F, Cianetti A, Zucchelli GC, Giovannini G, Pelizzola D. Supraregional interlaboratory quality-control survey for an immunoradiometric renin assay. Clin Chem 2001; 47: 2148-2150.
270. Arnal JF, Cudek P, Plouin PF, Guyenne TT, Michel JB, Corvol P. Low angiotensinogen levels are related to the severity and liver dysfunction of congestive heart failure: implications for renin measurements 1. Am J Med 1991; 90: 17-22.
271. Deinum J, Derkx FH, Schalekamp MA. Improved immunoradiometric assay for plasma renin. Clin Chem 1999; 45: 847-854.
272. Simon D, Hartmann DJ, Badouaille G, Caillot G, Guyenne TT, Corvol P, Pau B, Marchand J. Two-site direct immunoassay specific for active renin. Clin Chem 1992; 38: 1959-1962.
273. Sealey JE, Atlas SA, Laragh JH. Prorenin and other large molecular weight forms of renin. Endocr Rev 1980; 1: 365-391.
274. Derkx FH, Schalekamp MA. Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A 1988; 10: 1213-325.
275. Nielsen AH, Poulsen K. Is prorenin of physiological and clinical significance? J Hypertens 1988; 6: 949-958.
276. Sealey JE, Laragh JH. Renin and prorenin: advances and declines in methodology. Clin Chem 1996; 42: 993-994.
277. Morganti A, Pelizzola D, Mantero F, Gazzano G, Opocher G, Piffanelli A. Immunoradiometric versus enzymatic renin assay: results of the Italian Multicenter Comparative Study. Italian Multicenter Study for Standardization of Renin Measurement. J Hypertens 1995; 13: 19-26.
278. de Bruin RA, Bouhuizen A, Diederich S, Perschel FH, Boomsma F, Deinum J. Validation of a new automated renin assay. Clin Chem 2004; 50: 2111-2116.
279. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED, Jr., Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-885.
280. Fredline VF, Kovacs EM, Taylor PJ, Johnson AG. Measurement of plasma renin activity with use of HPLC-electrospray-tandem mass spectrometry. Clin Chem 1999; 45: 659-664.
281. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985; 7: I1-I7.
282. Souther ME, Lumpkin RH, Kuo KC, Reams GP, Bauer JH, Gehrke CW. High-performance liquid chromatographic-radioimmunoassay method for the measurement of angiotensin II peptides in human plasma. J Chromatogr 1987; 417: 27-40.
283. Kawamura M, Yoshida K, Akabane S, Matsushima Y, Kawano Y, Kojima S, Takahashi N, Shimamoto K, Ito K, Omae T. A sensitive method for precise measurement of endogenous angiotensins I, II&III in human plasma. Clin Exp Hypertens A 1987; 9: 687-691.
284. Hermann K, Ganten D, Unger T, Bayer C, Lang RE. Measurement and characterization of angiotensin peptides in plasma. Clin Chem 1988; 34: 1046-1051.
285. Huang H, Baussant T, Reade R, Michel JB, Corvol P. Measurement of angiotensin II concentration in rat plasma: pathophysiological applications. Clin Exp Hypertens A 1989; 11: 1535-1548.
286. Hanssens M, Keirse MJ, Lijnen PJ, Kucharski MJ, Luyten C, Van Assche FA. Measurement of individual angiotensin peptides by HPLC-RIA. J Biochem Biophys Methods 1990; 21: 103-113.
287. Hermann K, Ring J, Phillips MI. High-performance liquid chromatography for the separation of angiotensin and its metabolites in human plasma and sweat. J Chromatogr Sci 1990; 28: 524-528.
288. Campbell DJ, Kladis A. Simultaneous radioimmunoassay of six angiotensin peptides in arterial and venous plasma of man. J Hypertens 1990; 8: 165-172.
289. Simon D, Romestand B, Huang H, Badouaille G, Fehrentz JA, Pau B, Marchand J, Corvol P. Direct, simplified, and sensitive assay of angiotensin II in plasma extracts performed with a high-affinity monoclonal antibody. Clin Chem 1992; 38: 1963-1967.
290. Stewart PM. The adrenal cortex. In Larsen PR, Kronenberg HM, Melmed S, Polonski KS, Eds. Williams Textbook of Endocrinology, 10th Ed., Pp 491-551. Philadelphia: Saunders, 2003.
291. Orth DN. Cushing's syndrome. N Engl J Med 1995; 332: 791-803.
292. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647-672.
293. Nieman LK. Diagnostic tests for Cushing's syndrome. Ann NY Acad Sci 2002; 970: 112-118.
294. Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism 1979; 28: 955-977.
295. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602.
296. Bolufer P, Gandia A, Rodriguez A, Antonio P. Salivary corticosteroids in the study of adrenal function. Clin Chim Acta 1989; 183: 217-225.
297. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43: 545-550.
298. Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 1998; 83: 2681-2686.
299. Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84: 878-882.
300. Yaneva M, Mosnier-Pudar H, Dugue MA, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 2004; 89: 3345-3351.
301. Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Muller B. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab 2005; 90: 5730-5736.
302. Flack MR, Oldfield EH, Cutler GB, Jr., Zweig MH, Malley JD, Chrousos GP, Loriaux DL, Nieman LK. Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med 1992; 116: 211-217.
303. Miller JL. MIS priorities for MSO's (management services organization) & clinics without walls. Integr Healthc Rep 1994 Jan; 7-9.
304. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Arq Bras Endocrinol Metabol 2004; 48: 682-686.
305. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556.
306. New MI, Geller DS, Fallo F, Wilson RC. Monogenic low renin hypertension. Trends Endocrinol Metab 2005; 16: 92-97.
307. Mulatero P, Veglio F, Pilon C, Rabbia F, Zocchi C, Limone P, Boscaro M, Sonino N, Fallo F. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83: 2573-2575.
308. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991; 18: 283-286.
309. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem Mol Biol 2001; 78: 215-229.
310. Luft FC. Mendelian forms of human hypertension and mechanisms of disease. Clin Med Res 2003; 1: 291-300.
311. Mein CA, Caulfield MJ, Dobson RJ, Munroe PB. Genetics of essential hypertension. Hum Mol Genet 2004; 13 Spec No 1: R169-R175.
312. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP. Human hypertension caused by mutations in WNK kinases. Science 2001; 293: 1107-1112.
313. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New MI. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49: 757-764.
314. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 1988; 82: 340-349.
315. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-989.
316. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-585.
317. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80: 2263-2266.
318. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394-399.
319. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996; 347: 88-91.
320. Monder C, Shackleton CH, Bradlow HL, New MI, Stoner E, Iohan F, Lakshmi V. The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 betareductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 1986; 63: 550-557.
321. Luft FC. Molecular genetics of salt-sensitivity and hypertension. Drug Metab Dispos 2001; 29: 500-504.
322. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2: 821-824.
323. Farese RV, Jr., Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1223-1227.
324. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, Rossier BC. Amiloridesensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367: 463-467.
325. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR, Jr., Ulick S, Milora RV, Findling JW, Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79: 407-414.
326. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995; 11: 76-82.
327. Hansson JH, Schild L, Lu Y, Wilson TA, Gautschi I, Shimkets R, Nelson-Williams C, Rossier BC, Lifton RP. Ade novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA 1995; 92: 11495-11499.
328. Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle's syndrome revisited - a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994; 330: 178-181.
329. Persu A, Barbry P, Bassilana F, Houot AM, Mengual R, Lazdunski M, Corvol P, Jeunemaitre X. Genetic analysis of the beta subunit of the epithelial Na+ channel in essential hypertension. Hypertension 1998; 32: 129-137.
330. Hummler E, Horisberger JD. Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Am J Physiol 1999; 276: G567-G571.
331. Blythe WB. Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 1985; 5: A50-A56.
332. Martinez-Maldonado M. Role of hypertension in the progression of chronic renal disease. Nephrol Dial Transplant 2001; 16 Suppl 1: 63-66.
333. Whitworth JA. Progression of renal failure - the role of hypertension. Ann Acad Med Singapore 2005; 34: 8-15.
334. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
335. Abbott KC, Trespalacios FC, Welch PG, Agodoa LY. Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 2002; 15: 236-240.
336. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29: 315-333.
337. O'Callaghan CA. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumatol 2004; 18: 411-427.
338. First MR. Tacrolimus based immunosuppression. J Nephrol 2004; 17 Suppl 8: S25-S31.
339. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289-1293.
340. Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26: 461-468.
341. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21: 280-288.
342. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-297.
343. Agarwal R. Hypertension and survival in chronic hemodialysis patients-past lessons and future opportunities. Kidney Int 2005; 67: 1-13.
344. Hernandez D, Alvarez A, Torres A, Oppenheimer F, Cobo M, Gonzalez-Posada J, Jimenez A, Lorenzo V, Torregrosa V. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc 2003; 35: 1727-1729.
345. Margreiter R, Pohanka E, Sparacino V, Sperschneider H, Kunzendorf U, Huber W, Lameire N, Andreucci VE, Donati D, Heemann U. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transpl Int 2005; 18: 816-823.
346. Newstead CG. Recurrent disease in renal transplants. Nephrol Dial Transplant 2003; 18 Suppl 6: vi68-vi74.
347. Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M, Hunsicker LG. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125Iiothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16: 224-235.
348. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998; 32: 23-31.
349. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
350. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62: 249-256.
351. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
352. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright J, Jr. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 2001; 38: 744-753.
353. Weitgasser R, Schnoell F, Gappmayer B, Kartnig I. Prospective evaluation of urinary N-acetylbeta-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care 1999; 22: 1882-1886.
354. Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147: 943-944.
355. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998; 316: 504-509.
356. Richards NT, Darby S, Howie AJ, Adu D, Michael J. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9: 1255-1259.
357. Cohen AH, Nast CC, Adler SG, Kopple JD. Clinical utility of kidney biopsies in the diagnosis and management of renal disease. Am J Nephrol 1989; 9: 309-315.
358. Korbet SM. Percutaneous renal biopsy. Semin Nephrol 2002; 22: 254-267.
359. Fogo AB. Approach to renal biopsy. Am J Kidney Dis 2003; 42: 826-836.
360. Conn JW, Cohen EL, Lucas CP, McDonald WJ, Mayor GH, Blough WM, Jr., Eveland WC, Bookstein JJ, Lapides J. Primary reninism. Hypertension, hyperreninemia, and secondary aldosteronism due to renin-producing juxtaglomerular cell tumors. Arch Intern Med 1972; 130: 682-696.
361. Chambo JL, Falci JR, Lucon AM. Juxtaglomerular cell tumor as a rare cause of hypertension in adults. Int Braz J Urol 2004; 30: 119-120.
362. Saito I, Ito K, Saruta T. Hypothyroidism as a cause of hypertension. Hypertension 1983; 5: 112-115.
363. Fletcher AK, Weetman AP. Hypertension and hypothyroidism. J Hum Hypertens 1998; 12: 79-82.
364. Woeber KA. Update on the management of hyperthyroidism and hypothyroidism. Arch Fam Med 2000; 9: 743-747.
365. Marcisz C, Jonderko G, Kucharz E. Changes of arterial pressure in patients with hyperthyroidism during therapy. Med Sci Monit 2002; 8: CR502-CR507.
366. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990; 88: 626-630.
367. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-509.
368. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002; 87: 1996-2000.
369. Dzau VJ, Herrmann HC. Hormonal control of angiotensinogen production. Life Sci 1982; 30: 577-584.
370. Sergev O, Racz K, Varga I, Kiss R, Futo L, Mohari K, Glaz E. Thyrotropin-releasing hormone increases plasma atrial natriuretic peptide levels in human. J Endocrinol Invest 1990; 13: 649-652.
371. Hanna FW, Scanlon MF. Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Lancet 1997; 350: 755-756.
372. Montenegro J, Gonzalez O, Saracho R, Aguirre R, Gonzalez O, Martinez I. Changes in renal function in primary hypothyroidism. Am J Kidney Dis 1996; 27: 195-198.
373. Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 1997; 85: 734-738.
374. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley EJ, Hasan DM, Rodgers H, Tunbridge F, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55-68.
375. Toft AD, Boon NA. Thyroid disease and the heart. Heart 2000; 84: 455-460.
376. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499.
377. Streeten DH, Anderson GH, Jr., Howland T, Chiang R, Smulyan H. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 1988; 11: 78-83.
378. Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med 2001; 345: 260-265.
379. Sahun M, Villabona C, Rosel P, Navarro MA, Ramon JM, Gomez JM, Soler J. Water metabolism disturbances at different stages of primary thyroid failure. J Endocrinol 2001; 168: 435-445.
380. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001; 345: 512-516.
381. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12: 421-425.
382. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-238.
383. Klein I, Levey GS. New perspectives on thyroid hormone, catecholamines, and the heart. Am J Med 1984; 76: 167-172.
384. Fraser R, Davies DL, Connell JM. Hormones and hypertension. Clin Endocrinol (Oxf) 1989; 31: 701-746.
385. Wang HH. Reporting thyroid fine-needle aspiration: literature review and a proposal. Diagn Cytopathol 2006; 34: 67-76.
386. Khati N, Adamson T, Johnson KS, Hill MC. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q 2003; 19: 162-176.
387. Stockigt JR. Case finding and screening strategies for thyroid dysfunction. Clin Chim Acta 2002; 315: 111-124.
388. Helfand M, Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998; 129: 144-158.
389. Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in hospitalized patients: a systematic review. Arch Intern Med 1999; 159: 658-665.
390. Kaplan MM. Clinical perspectives in the diagnosis of thyroid disease. Clin Chem 1999; 45: 1377-1383.
391. Garcia dlT, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 2003; 10: 309-322.
392. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease-a review. Eur Heart J 2004; 25: 1776-1787.
393. Broulik PD, Horky K, Pacovsky V. Blood pressure in patients with primary hyperparathyroidism before and after parathyroidectomy. Exp Clin Endocrinol 1985; 86: 346-352.
394. Uden P, Chan A, Duh QY, Siperstein A, Clark OH. Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery. World J Surg 1992; 16: 791-797.
395. Salahudeen AK, Thomas TH, Sellars L, Tapster S, Keavey P, Farndon JR, Johnston ID, Wilkinson R. Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clin Sci (Lond) 1989; 76: 289-296.
396. Sancho JJ, Rouco J, Riera-Vidal R, Sitges-Serra A. Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992; 16: 732-735.
397. Rodriguez-Portales JA, Fardella C. Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure. J Endocrinol Invest 1994; 17: 307-311.
398. Younes NA, Shafagoj Y, Khatib F, Ababneh M. Laboratory screening for hyperparathyroidism. Clin Chim Acta 2005; 353: 1-12.
399. Gordon RD, Laragh JH, Funder JW. Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab 2005; 16: 108-113.
400. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 Suppl 1: 121-124.
401. Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc 2004; 36: 229S-33S.
402. Tilney NL, Milford EL, Araujo JL, Strom TB, Carpenter CB, Kirkman RL. Experience with cyclosporine and steroids in clinical renal transplantation. Ann Surg 1984; 200: 605-613.
403. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC, Jr., Gores G, Hay E, Dickson ER, Krom RA. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332-1339.
404. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E, Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443.
405. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
406. Kramer BK, Boger C, Kruger B, Marienhagen J, Pietrzyk M, Obed A, Paczek L, Mack M, Banas B. Cardiovascular risk estimates and risk factors in renal transplant recipients. Transplant Proc 2005; 37: 1868-1870.
407. Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990; 1: 76-83.
408. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100-1106.
409. Ovuworie CA, Fox ER, Chow CM, Pascual M, Shih VE, Picard MH, Tolkoff-Rubin NE. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. Transplantation 2001; 72: 1385-1388.
410. Calò LA, Davis PA, Giacon B, Pagnin E, Sartori M, Riegler P, Antonello A, Huber W, Semplicini A. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol 2002; 40: 625-631.
411. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, Hanson P, Mohanty PK, Victor RG. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693-699.
412. Nitta K, Friedman AL, Nicastri AD, Paik S, Friedman EA. Granular juxtaglomerular cell hyperplasia caused by cyclosporine. Transplantation 1987; 44: 417-421.
413. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland SJ, Alpers CE, Bennett WM, Couser WG, Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-1196.
414. Wong W, Tolkoff-Rubin N, Delmonico FL, Cardarelli F, Saidman SL, Farrell ML, Shih V, Winkelmayer WC, Cosimi AB, Pascual M. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant 2004; 18: 341-348.
415. Tuncel M, Wang Z, Arbique D, Fadel PJ, Victor RG, Vongpatanasin W. Mechanism of the blood pressure-raising effect of cocaine in humans. Circulation 2002; 105: 1054-1059.
416. Linder MW, Bosse GM, Henderson MT, Midkiff G, Valdes R. Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clin Chim Acta 2000; 295: 179-185.
417. Schramm W, Craig PA, Smith RH, Berger GE. Cocaine and benzoylecgonine in saliva, serum, and urine. Clin Chem 1993; 39: 481-487.
418. Phillips DL, Tebbett IR, Bertholf RL. Comparison of HPLC and GC-MS for measurement cocaine and metabolites in human urine. J Anal Toxicol 1996; 20: 305-308.